Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Padeliporfin vascular targeted photodynamic therapy for obstructing endobronchial non-small cell lung cancer
2009-011895-31Phase 2Active
- Sponsor
- Steba Biotech
- Start
- Jul 2009
- Modality
- Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of padeliporfin VTP in non-small cell lung cancer (NSCLC), sponsored by Steba Biotech. Primary endpoint: Bronchial desobstruction efficacy. Started Jul 2009; status: active.
02
Drugs
padeliporfin VTP
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2009-011895-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011895-31.